Skip to main content

Grafa News and Videos — Page 1583

Latest

Grafa

Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer

Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.

Read more: Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer
Grafa
Mining

Namib Minerals posts EBITDA growth as strategic expansions move toward 2026 milestones

Namib Minerals (NASDAQ:NAMM) reported a resilient fiscal 2025 performance, characterized by rising profitability and steady progress on its multi-asset growth strategy in Zimbabwe, despite a slight dip in annual gold production.

Read more: Namib Minerals posts EBITDA growth as strategic expansions move toward 2026 milestones
Grafa
Agriculture

ScottsMiracle-Gro shields margins with domestic sourcing as 2026 targets reaffirmed

ScottsMiracle-Gro (NYSE:SMG) has reaffirmed its fiscal 2026 financial guidance, signaling confidence in its margin recovery plan by highlighting a supply chain largely insulated from international volatility and inflationary spikes.

Read more: ScottsMiracle-Gro shields margins with domestic sourcing as 2026 targets reaffirmed
Grafa

Adagene and Incyte form alliance to target treatment-resistant colorectal cancer

Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.

Read more: Adagene and Incyte form alliance to target treatment-resistant colorectal cancer
Grafa

AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study

AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.

Read more: AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study
Grafa

Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy

Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.

Read more: Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy
Grafa
Technology

Lindsay profits profits slump as demand eases across irrigation and Infrastructure

Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.

Read more: Lindsay profits profits slump as demand eases across irrigation and Infrastructure

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift